Description
AGLink® ADC Conjugation Kit (MMAE, DAR4, 2mg) | ADC-P001| Gentaur Distribution US, UK & Europe
Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGlink ADC conjugation kit is designed to conjugate mAb with toxic payload (MMAE) though site-specific enzymatic reaction.
Source: Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGlink ADC conjugation kit is designed to conjugate mAb with toxic payload (MMAE) though site-specific enzymatic reaction.
Molecule: GDPN/AFucN/AvcN/APABN/AMMAE.
Format: Solid.
Species: N/A.
Application: AGLink® ADC Conjugation Kit (MMAE, DAR4, 2mg) is designed to conjugate 2mg mAb with toxic payload (MMAE) through site-specific enzymatic reaction.
Kit Component: N/A.
Stability: BoxA: The unopened kit is stable for 12 months from the date of manufacture if stored under temperature ≤ -20°C. The opened kit should be stored according to components table. BoxB: The unopened kit is stable for 12 months from the date of manufacture if stored under 4°C. The opened kit should be stored according to components table.
Storage Conditions: -20℃.
Shipping Conditions: Blue ice
